Molecular Cardiology Research Institute, Tufts Medical Center , Boston, Massachusetts.
Tufts University School of Medicine , Boston, Massachusetts.
Am J Physiol Heart Circ Physiol. 2019 Jan 1;316(1):H145-H159. doi: 10.1152/ajpheart.00029.2018. Epub 2018 Oct 26.
Myocardial hypertrophy is an independent risk factor for heart failure (HF), yet the mechanisms underlying pathological cardiomyocyte growth are incompletely understood. The c-Jun NH-terminal kinase (JNK) signaling cascade modulates cardiac hypertrophic remodeling, but the upstream factors regulating myocardial JNK activity remain unclear. In this study, we sought to identify JNK-activating molecules as novel regulators of cardiac remodeling in HF. We investigated mixed lineage kinase-3 (MLK3), a master regulator of upstream JNK-activating kinases, whose role in the remodeling process had not previously been studied. We observed increased MLK3 protein expression in myocardium from patients with nonischemic and hypertrophic cardiomyopathy and in hearts of mice subjected to transverse aortic constriction (TAC). Mice with genetic deletion of MLK3 (MLK3) exhibited baseline cardiac hypertrophy with preserved cardiac function. MLK3 mice subjected to chronic left ventricular (LV) pressure overload (TAC, 4 wk) developed worsened cardiac dysfunction and increased LV chamber size compared with MLK3 littermates ( n = 8). LV mass, pathological markers of hypertrophy ( Nppa, Nppb), and cardiomyocyte size were elevated in MLK3 TAC hearts. Phosphorylation of JNK, but not other MAPK pathways, was selectively impaired in MLK3 TAC hearts. In adult rat cardiomyocytes, pharmacological MLK3 kinase inhibition using URMC-099 blocked JNK phosphorylation induced by neurohormonal agents and oxidants. Sustained URMC-099 exposure induced cardiomyocyte hypertrophy. These data demonstrate that MLK3 prevents adverse cardiac remodeling in the setting of pressure overload. Mechanistically, MLK3 activates JNK, which in turn opposes cardiomyocyte hypertrophy. These results support modulation of MLK3 as a potential therapeutic approach in HF. NEW & NOTEWORTHY Here, we identified a role for mixed lineage kinase-3 (MLK3) as a novel antihypertrophic and antiremodeling molecule in response to cardiac pressure overload. MLK3 regulates phosphorylation of the stress-responsive JNK kinase in response to pressure overload and in cultured cardiomyocytes stimulated with hypertrophic agonists and oxidants. This study reveals MLK3-JNK signaling as a novel cardioprotective signaling axis in the setting of pressure overload.
心肌肥厚是心力衰竭(HF)的独立危险因素,但病理性心肌细胞生长的机制尚不完全清楚。c-Jun NH-末端激酶(JNK)信号级联调节心脏肥厚重塑,但调节心肌 JNK 活性的上游因素仍不清楚。在这项研究中,我们试图确定 JNK 激活分子作为 HF 中心脏重塑的新型调节剂。我们研究了混合谱系激酶-3(MLK3),它是上游 JNK 激活激酶的主要调节剂,其在重塑过程中的作用以前尚未研究过。我们观察到非缺血性和肥厚性心肌病患者的心肌以及接受横主动脉缩窄(TAC)的小鼠的心肌中 MLK3 蛋白表达增加。MLK3 基因缺失(MLK3)的小鼠在基线时表现出心肌肥厚,且心脏功能正常。与 MLK3 同窝仔鼠(n = 8)相比,MLK3 小鼠接受慢性左心室(LV)压力超负荷(TAC,4 周)后心脏功能恶化,LV 腔室增大。LV 质量、肥厚的病理标志物(Nppa、Nppb)和心肌细胞大小在 MLK3 TAC 心脏中升高。MLK3 TAC 心脏中 JNK 的磷酸化(但不是其他 MAPK 途径)选择性受损。在成年大鼠心肌细胞中,使用 URMC-099 进行药理学 MLK3 激酶抑制可阻断神经激素和氧化剂诱导的 JNK 磷酸化。持续暴露于 URMC-099 可诱导心肌细胞肥大。这些数据表明 MLK3 可防止压力超负荷情况下的心脏不良重塑。从机制上讲,MLK3 激活 JNK,而 JNK 反过来又对抗心肌细胞肥大。这些结果支持调节 MLK3 作为 HF 的一种潜在治疗方法。
这项研究发现了混合谱系激酶-3(MLK3)在心脏压力超负荷时作为一种新型抗肥厚和抗重塑分子的作用。MLK3 调节应激响应的 JNK 激酶在压力超负荷以及用肥大激动剂和氧化剂刺激培养的心肌细胞中的磷酸化。这项研究揭示了 MLK3-JNK 信号作为压力超负荷时的一种新型心脏保护信号轴。